337 Results for "

Preclinical

" in MedChemExpress (MCE) Product Catalog:
Products (337)

337 Results for "Preclinical" in MCE Product Catalog:

17
17 Publications Verification
Cat. No.: HY-13241A
CAS No.: 862505-00-8
Synonyms: LY2228820
Target:  

p38 MAPK Autophagy

Research Areas:  

Cancer

Ralimetinib is an ATP-competitive p38α and p38β MAPK inhibitor with an IC50 of 5.3 nmol/L against human p38α and an IC50 of 3.2 nmol/L against human p38β. Ralimetinib slows tumor growth in preclinical in vivo cancer models, exhibits oral bioavailability in mice, and achieves sustained target inhibition for 4 to 8 h. Ralimetinib is applicable for research on melanoma, non-small cell lung cancer, ovarian cancer, glioma, multiple myeloma, breast cancer, renal cancer, and head and neck squamous cell carcinoma .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-100754
CAS No.: 1792180-81-4
Purity:  99.43%
Synonyms: PF-06651600
Research Areas:  

Inflammation/Immunology

Ritlecitinib (PF-06651600) is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC50 >10 μ M). Ritlecitinib rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE) .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-100754C
CAS No.: 2192215-81-7
Purity:  99.77%
Synonyms: PF-06651600 tosylate
Research Areas:  

Inflammation/Immunology

Ritlecitinib (PF-06651600) tosylate is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC50 >10 μ M). Ritlecitinib tosylate rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib tosylate can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE) .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-147214
CAS No.: 2648450-42-2
Purity:  99.54%
Target:  

YAP

Research Areas:  

Cancer

GNE-7883 is a pan-TEAD inhibitor that blocks the association of YAP/TAZ with TEAD. GNE-7883 effectively reduces chromatin accessibility at TEAD motifs, inhibits cell proliferation in multiple cell line models, and achieves strong anti-tumor efficacy in vivo. In addition, GNE-7883 effectively overcomes intrinsic and acquired resistance to KRAS (Kirsten rat sarcoma viral oncogene homolog) G12C inhibitors in multiple preclinical models by inhibiting YAP/TAZ activation .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-D1191
CAS No.: 2225748-05-8
SYBR Green I chloride is a highly sensitive fluorescent nucleic acid dye that binds specifically to the minor groove of double-stranded DNA or intercalates between base pairs. SYBR Green I chloride exhibits weak fluorescence in the unbound state but emits bright fluorescence upon binding, and it preferentially binds to large-fragment DNA and DNA with high G+C content. SYBR Green I chloride is suitable for real-time PCR technology; its fluorescence intensity correlates with the amount and size of amplification products, enabling accurate quantification of gene expression and discrimination of amplicons via melting curve analysis without additional post-processing. SYBR Green I chloride is widely used in preclinical in vitro nucleic acid detection .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-164992
Synonyms: MRG002; Trastuzumab MMAE
Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a Kd of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-156654
CAS No.: 2755812-39-4
Purity:  99.90%
Synonyms: PF-07817883
Target:  

SARS-CoV Virus Protease

Research Areas:  

Infection

Ibuzatrelvir (PF-07817883), a second-generation, orally bioavailable, is SARS-CoV-2 main protease (M pro and 3CL pro) inhibitor with improved metabolic stability. Ibuzatrelvir has demonstrated pan-human coronavirus antiviral activity and off-target selectivity profile in vitro and in preclinical animal studies. Ibuzatrelvir is well tolerated with a safety profile similar to placebo and prevents viral infection and transmission. Ibuzatrelvir can be used to inhibit COVID-19 .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99463
CAS No.: 2268717-61-7
Synonyms: AVB-500; AVB-S6-500

Research Areas:  

Cancer

Batiraxcept (AVB-500; AVB-S6-500) is a selective, soluble AXL receptor and GAS6 inhibitor that targets the GAS6-AXL signaling axis. Batiraxcept is orally inactive and does not cross the blood-brain barrier. Batiraxcept competitively binds to GAS6 ((KD <1 nM), preventing its interaction with the AXL receptor tyrosine kinase, thereby inhibiting downstream PI3K/AKT and MAPK signaling pathways, reducing tumor cell glycolysis, angiogenesis, and metastatic potential. Batiraxcept has demonstrated antitumor activity in preclinical models of endometrial, cholangiocarcinoma, and ovarian cancer by inhibiting tumor growth, invasion, and metastasis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-119024
CAS No.: 112170-24-8
Purity:  98.88%
Target:  

SHP1 STAT

Research Areas:  

Cancer

BCI-137 is a Argonaute 2 (AGO2) inhibitor. By inhibiting AGO2 function, reducing PTPN6/SHP-1 protein levels and enhancing STAT1 phosphorylation, BCI-137 restores the sensitivity of tumor cells to IFN-γ. BCI-137 effectively enhances the recruitment, activation and cytotoxicity of CD8 + T cells. BCI-137 exerts a synergistic effect with anti-PD-1 antibodies and significantly reduces tumor volume in preclinical mouse models. BCI-137 exhibits favorable safety profiles and does not cause significant weight loss or death in mice. BCI-137 can be used in research related to bladder cancer, colorectal cancer, melanoma and other related fields .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-W129633
CAS No.: 1266615-56-8
Synonyms: DCIP sodium hydrate; DPIP sodium hydrate
2,6-Dichlorophenolindophenol (DCIP; DPIP) sodium hydrate is a redox chromogenic indicator with a redox potential of +217 mV relative to SHE, and it acts as a substrate for reduction reactions. During the metabolic process of nutrient consumption by Saccharomyces cerevisiae, 2,6-Dichlorophenolindophenol sodium hydrate is reduced from dark blue to colorless, resulting in a decrease in absorbance. 2,6-Dichlorophenolindophenol sodium hydrate is widely used in spectrophotometric biochemical oxygen demand determination and preclinical colorimetric toxicity analysis for heavy metal ion detection based on Saccharomyces cerevisiae .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-117604
CAS No.: 1257051-63-0
Purity:  98.75%
Research Areas:  

Neurological Disease

THPP-1, a SGC chemical probe, is a potent and orally bioavailable phosphodiesterase 10A (PDE10A) inhibitor, with Ki values of 1 nM and 1.3 nM for human and rat PDE10A, respectively. THPP-1 has excellent pharmacokinetic properties in preclinical species .
loading...
    loading...
Cat. No.: HY-157941
CAS No.: 2267316-76-5
Purity:  99.89%
Synonyms: ART0380
Research Areas:  

Cancer

ART0380 is a potent, selective and orally active ATR kinase inhibitor. ART0380 potently inhibits human ATR-ATRIP complex with an IC50 of 51.7 nM. ART0380 binds the ATP pocket of the ATR-ATRIP complex, blocks ATR-dependent Chk1 serine 345 phosphorylation, and induces cell cycle disorder and DNA damage. ART0380 demonstrates potent and selective antitumor activity in preclinical models with varying types of ataxia-telangiectasia mutated (ATM) gene aberrancy. ART0380 can be used for the research of cancer, such as colorectal cancer and prostate cancer .
loading...
    loading...
Cat. No.: HY-P990673
Synonyms: DSTP-3086S Antibody; RG-7450 Antibody

Research Areas:  

Cancer

Vandortuzumab (DSTP-3086S Antibody; RG-7450 Antibody) is a humanized anti-STEAP1 IgG1 antibody and antimitotic agent that can be conjugated with MMAE (HY-15162) to form the antibody-drug conjugate (ADC) Vandortuzumab vedotin. Vandortuzumab vedotin specifically binds to STEAP1 and drives internalization of the complex, releasing the MMAE (HY-15162) payload intracellularly. After binding to tubulin, MMAE inhibits cell division and induces cell death. Vandortuzumab exhibits antitumor activity in preclinical xenograft models of prostate cancer and can be used for research related to metastatic castration-resistant prostate cancer (mCRPC) .
loading...
    loading...
Cat. No.: HY-P99101
CAS No.: 2490556-50-6
Synonyms: AEX-4089; MGC026 antibody

Target:  

ADC Antibodies

Research Areas:  

Cancer

Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma .
loading...
    loading...
Cat. No.: HY-P990083
CAS No.: 2628092-47-5
Synonyms: AT-1501

Target:  

TNF Receptor

Research Areas:  

Inflammation/Immunology

Tegoprubart (AT-1501) is a CD40 ligand inhibitor (EC50=100 ng/mL) and immunosuppressant that selectively inhibits the CD40 ligand, a co-stimulatory molecule involved in T cell activation. Tegoprubart suppresses immune rejection, prevents rejection in animal transplantation models, and reduces cell-mediated and antibody-mediated immune responses to create a more immunotolerant environment. Tegoprubart preserves renal function when combined with Mycophenolate (HY-B0421) and Corticosteroids, and maintains graft function in preclinical studies. Tegoprubart is applicable to research related to kidney transplantation and kidney transplant rejection .
loading...
    loading...
Cat. No.: HY-138799
CAS No.: 1636894-46-6
Purity:  99.24%
Target:  

HDAC

Research Areas:  

Cancer

KA2507 is a potent, orally active and selective HDAC6 inhibitor, with an IC50 of 2.5 nM. KA2507 shows antitumor activities and immune modulatory effects in preclinical models .
loading...
    loading...
Cat. No.: HY-118930
CAS No.: 455956-93-1
Purity:  99.02%
Target:  

Melanocortin Receptor

Research Areas:  

Metabolic Disease

MK-0493 is an orally active melanocortin-4 receptor (MC4R) agonist. MK-0493 reduces food intake, suppresses weight gain, elevates blood pressure at high doses, and exhibits preclinical erectile regulatory activity. MK-0493 can be used in research related to obesity .
loading...
    loading...
Cat. No.: HY-P99317
CAS No.: 955085-14-0
Synonyms: LY-2062430

Target:  

Amyloid-β

Research Areas:  

Neurological Disease

Solanezumab (LY-2062430) is a humanized monoclonal IgG1 antibody directed against the mid-domain of the amyloid-β () peptide. Solanezumab binds to the mid-domain of monomeric amyloid-beta to slow brain amyloid accumulation. Solanezumab can be used for the research of Alzheimer’s disease .
loading...
    loading...
Cat. No.: HY-162567
CAS No.: 2716909-84-9
Target:  

HSP Beclin1 Autophagy

Research Areas:  

Cancer

AP-4-139B is a blood-brain barrier-permeable HSP70 inhibitor with a IC50 of 180 nM against hHSP70. AP-4-139B binds directly to HSP70 and inhibits its ATPase activity. AP-4-139B promotes Autophagy by increasing the phosphorylation of Beclin-1. AP-4-139B exerts antitumor effects in preclinical models of colorectal cancer and pancreatic ductal adenocarcinoma .
loading...
    loading...
Cat. No.: HY-114301
CAS No.: 1449473-97-5
Purity:  99.92%
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

PF-06305591 is a potent and highly selective voltage gated sodium channel NaV1.8 blocker, with an IC50 of 15 nM. An excellent preclinical in vitro ADME and safety profile .
loading...
    loading...